
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Appropriate evaluation and treatment of fractures of the distal radius, elbow, clavicle, and tibia hinge on the clinician?s recognition of mechanisms and patterns of injury and physical and radiographic findings.






